Vinay Sikand, MD
Pulmonary Disease · Toms River, NJNPI 1568499374
Payments from drug & device makers
Across 1,522 payments — averaging $1210.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1M
- GSK$365K
- Genentech, Inc.$273K
- Astrazeneca AB$65K
- Insmed, Inc.$37K
- Teva Pharmaceuticals USA, Inc.$25K
- plus $44K from 42 others
Across 14 payments — averaging $102.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1K
What the payments were for
- Speaking & faculty fees$65,77568%
- Travel & lodging$7,8608%
- Food & beverage$21,99923%
- Education$5921%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$42,642
- AREXVY$10,189
- BREZTRI$3,130
- FASENRA$2,602
- ANORO ELLIPTA$1,200
- TEZSPIRE$910
- AIRSUPRA$465
- SYMBICORT$262
- DUPIXENT$235
- OFEV$232
- NUCALA$226
- BEVESPI AEROSPHERE$188
- ENROUTE Transcarotid Neuroprotection System$122
- ENROUTE Transcarotid Stent$122
- Inspire$117
- inCourage$102
How this compares
$1,842,221 in reported general payments places this provider in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 145 | $1,883,479 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 679 | $606,019 |
| OpsumitMacitentan | 43 | $546,256 |
| AdempasRiociguat | 15 | $203,908 |
| Orenitram ErTreprostinil Diolamine | 24 | $183,310 |
| Breo ElliptaFluticasone/Vilanterol | 213 | $148,540 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 162 | $145,683 |
| Fasenra PenBenralizumab | 24 | $134,655 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $133,764 |
| Dupixent PenDupilumab | 31 | $113,047 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 127 | $89,593 |
| NucalaMepolizumab | 22 | $89,536 |
| Spiriva RespimatTiotropium Bromide | 97 | $81,627 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 143 | $74,340 |
| Pirfenidone | 21 | $44,999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,496 | $2,098,467407 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $364,560 | $929,1261,089 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,287 | $546,25643 claims |
| BayerAdempas | $282 | $203,90815 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,033,635 | $174,465231 claims |
| Grifols USA, LLCProlastin C | $477 | $133,76412 claims |
| PfizerEliquis | $17 | $24,42723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Toms River
- Muhammad KhanToms River$15K
- Reynold PanettieriNew Brunswick$2.5M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.